Author

Shemeka Davis

Institutions: Vanderbilt University, Vanderbilt-Ingram Cancer Center

Observed institutions: Vanderbilt University, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

OpenAlex ID: A5063694635

All in the Levels—Programmed Death-Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Patients with Gastrointestinal Cancer

2020 · Satya Das, Sarah Cimino, et al. · The Oncologist · 4

Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).

2022 · Christopher G Cann, Sarah Cimino, et al. · Journal of Clinical Oncology · 2

Updated analysis: Effect of biweekly dosing schedule of trifluridine-tipiracil (TAS-102) on rates of myelosuppression and maintenance of therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).

2023 · Christopher G Cann, Michael Brian LaPelusa, et al. · Journal of Clinical Oncology

Works count: 3

Citation count: 6

H-index: 2

I10-index: